Severe cerebellitis as a manifestation of infliximab-associated overlap of neurosarcoidosis and myelin oligodendrocyte glycoprotein antibody-associated disease – case report - Summary - MDSpire

Severe cerebellitis as a manifestation of infliximab-associated overlap of neurosarcoidosis and myelin oligodendrocyte glycoprotein antibody-associated disease – case report

  • By

  • Gregor Hütter

  • Maximilian Winkelhausen

  • Lars Tönges

  • Ralf Gold

  • Simon Faissner

  • June 1, 2026

  • 0 min

Share

Objective:

To report a case of acute cerebellitis associated with infliximab therapy, highlighting the overlap of neurosarcoidosis and MOG antibody disease.

Key Findings:
  • Infliximab therapy can lead to paradoxical inflammatory reactions, including neurosarcoidosis and MOGAD.
  • Cerebellitis can occur in patients on TNF-α inhibitors, even in the absence of radiological findings.
Interpretation:

This case illustrates the complexity of diagnosing and managing acute cerebellitis in the context of TNF-α inhibitor therapy.

Limitations:
  • The case report is based on a single patient, limiting generalizability.
  • Long-term outcomes and potential recurrence of symptoms were not addressed.
Conclusion:

Clinicians should consider neurosarcoidosis and MOGAD in patients on TNF-α inhibitors presenting with neurological deficits.

Original Source(s)

Severe cerebellitis as a manifestation of infliximab-associated overlap of neurosarcoidosis and myelin oligodendrocyte glycoprotein antibody-associated disease – case report

  • by Gregor Hütter, Maximilian Winkelhausen, Lars Tönges, Ralf Gold, Simon Faissner

  • June 1, 2026

Related Content

Gray matter volume alterations in adolescents with ADHD are associated with cell type-specific transcriptional signatures

Handwriting Kinematics Differentiate Cognitive Impairment

“Diagnostic differentiation emerged only under tasks imposing higher cognitive-motor demands.”

Not All Poststroke Cognitive Patterns Plateau

Researchers identify divergent recovery, persistence, and decline patterns across cognitive domains following stroke.